ِDezAzma

GLP-1 Receptor Agonists: Clinically Oriented Overview for Clinicians

14 ژوئن 26

GLP-1 receptor agonists are incretin-based therapies initially developed for type 2 diabetes mellitus and now widely used in obesity and cardiometabolic risk management. They mimic endogenous glucagon-like peptide-1 (GLP-1), a gut-derived hormone involved in glucose regulation and appetite control.

1. Mechanism of Action

GLP-1 receptor agonists act through multiple physiological pathways:

Enhance glucose-dependent insulin secretion from pancreatic β-cells

Suppress glucagon secretion during hyperglycemia

Delay gastric emptying, reducing postprandial glucose excursions

Act centrally on the hypothalamus to reduce appetite and increase satiety

These combined effects improve glycemic control while reducing energy intake. ¹,¹³,¹⁴

2. Clinical Effects

Effects primarily mediated via appetite suppression and reduced caloric intake¹

Glycemic control

Significant reduction in HbA1c across multiple trials

Low intrinsic risk of hypoglycemia when not combined with insulin or sulfonylureas

Weight reduction

Clinically meaningful weight loss in patients with obesity and type 2 diabetes

Cardiovascular outcomes

Large cardiovascular outcome trials (CVOTs) and meta-analyses demonstrate:

Reduction in major adverse cardiovascular events (MACE) in high-risk populations

Decreased cardiovascular mortality in selected agents (e.g., liraglutide, semaglutide) ²,⁴,⁵,⁶,⁷

Renal and hepatic effects

Slower progression of albuminuria and eGFR decline in multiple analyses

Reduction in liver fat content and improvement in metabolic dysfunction–associated steatotic liver disease signals ⁴,¹¹,¹²

3. Evidence Base (Key Trials)

Major cardiovascular outcome trials include:

LEADER (liraglutide) ⁵

SUSTAIN-6 (semaglutide) ⁶

REWIND (dulaglutide) ⁷

EXSCEL (exenatide) ⁸

Across these studies, GLP-1 receptor agonists consistently demonstrated non-inferiority for cardiovascular safety, with several showing superiority for MACE reduction. ³,⁵–⁸

Meta-analyses confirm a class-wide reduction in cardiovascular events, particularly stroke and cardiovascular death in high-risk patients. ⁴

4. Adverse Effects and Safety

Common adverse effects:

Nausea

Vomiting

Diarrhea or constipation

Early satiety and abdominal discomfort

Important risks

Gallbladder disease (increased risk in some populations)

Rare pancreatitis (causal association remains debated)

Transient worsening of diabetic retinopathy with rapid glycemic improvement in selected trials

Tolerability considerations

Gastrointestinal adverse effects remain the primary limitation to adherence. Patient education and gradual titration are essential.

5. Contraindications and Precautions

Personal or family history of medullary thyroid carcinoma (based on preclinical rodent findings)

Multiple endocrine neoplasia type 2 (MEN2)

Caution in severe gastrointestinal motility disorders

Monitoring recommended in patients with advanced renal disease due to dehydration risk

6. Clinical Use Considerations

Often used in combination with metformin, SGLT2 inhibitors, or insulin.

Insulin or sulfonylurea doses may require reduction to prevent hypoglycemia

Long-term therapy is often required to maintain weight and metabolic benefits

Discontinuation is frequently associated with partial weight regain

7. Current Research Directions

Dual and triple incretin agonists (e.g., GLP-1/GIP combinations)

Oral formulations with improved bioavailability

Expansion of cardiovascular and renal outcome indications

Investigation of neuropsychiatric, inflammatory, and metabolic effects beyond diabetes ¹⁰,¹³,¹⁴

Summary

GLP-1 receptor agonists represent a class of multisystem metabolic therapies that improve glycemic control, promote weight loss, and reduce cardiovascular risk in selected populations. Their clinical utility extends beyond glucose lowering into integrated cardiometabolic disease modification. However, long-term adherence, gastrointestinal tolerability, and cost remain key limitations.

References:

1. Ussher JR, Drucker DJ

Glucagon-like peptide-1 receptor agonists: cardiovascular benefits and mechanisms of action.
Nature Reviews Cardiology (2023)

2. Bethel MA, et al.

Cardiovascular outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: meta-analysis.
Lancet Diabetes & Endocrinology (2018)

3. Urquhart S, Willis S

Long-acting GLP-1 receptor agonists: implications of cardiovascular outcome trials.
JAAPA (2020)

4. Kristensen SL, et al.

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists: systematic review and meta-analysis.
Lancet Diabetes & Endocrinology (2019)

5. Marso SP, et al. (LEADER)

Liraglutide and cardiovascular outcomes in type 2 diabetes.
New England Journal of Medicine (2016)

6. Marso SP, et al. (SUSTAIN-6)